November 19, 2026 at 10:01 PM UTC
PharmaCyte Biotech, Inc. reports material agreement in SEC 8-K
PharmaCyte Biotech, Inc. filed an 8-K covering a material definitive agreement and an acquisition or disposition of assets. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.
Official source: U.S. Securities and Exchange Commission
Official source published: November 19, 2026 at 10:00 PM UTC
Open official source